Melanoma Blood Test and Survival
Author Information
Author(s): Proebstle T M, Jiang W, Högel J, Keilholz U, Weber L, Voit C
Primary Institution: Department of Dermatology, University of Mainz, Mainz, Germany
Hypothesis
The study investigates the correlation between positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients and their clinical stage, survival, and other risk factors.
Conclusion
The study found that positive RT-PCR for tyrosinase in melanoma patients is associated with poorer survival outcomes.
Supporting Evidence
- Positive tyrosinase RT-PCR results were found in 11% of stage I patients and 67% of stage IV patients.
- Stage III patients with positive RT-PCR had a shorter disease-free interval compared to negative patients.
- Median overall survival for stage IV patients with positive RT-PCR was 8 months compared to 12 months for negative tests.
Takeaway
Doctors can test blood for a substance called tyrosinase to help understand how serious melanoma is and how long patients might live.
Methodology
The study examined 212 blood samples from melanoma patients, using RT-PCR to detect tyrosinase transcripts.
Participant Demographics
Patients were from all clinical stages of melanoma.
Statistical Information
P-Value
0.0001
Confidence Interval
8.53–45.5
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website